- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07947966
Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of REGN20566 in Adult Participants With Overweight or Obesity
This study will test a Regeneron drug called REGN20566 ("study drug") to see how safe it is and how participants with overweight or obesity respond to it.
The study will be split into two parts, Part A and Part B.
The study is looking at:
- What side effects REGN20566 might cause
- How much REGN20566 is in the blood at different times
- If the body reacts to REGN20566 in a way that may cause REGN20566 to not work as well
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Total planned duration of trial participation for each participant (excluding screening period):
- Part A: approximately 16 weeks
- Part B: approximately 27 weeks
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Trials Administrator
- Phone Number: 844-734-6643
- Email: clinicaltrials@regeneron.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Has a body mass index 27-40 kg/m2, inclusive, at screening visit or prior to randomization
- Healthy volunteers with obesity
Key Exclusion Criteria:
- A self-reported change of body weight >5 kg within 90 days of screening visit
- History of type 1 or 2 diabetes, or bariatric surgery
- Hemoglobin A1c (HbA1c) ≥6.5% at the screening visit
- History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease
- Received a nutrient stimulating hormone (NuSH)-based therapy (eg, Glucagon-like peptide-1 receptor agonist [GLP-1RA]) within 6 months of the screening visit
- Planned initiation of NuSH-based therapy, bariatric surgery, or alternative procedures aimed at reducing weight or altering of body composition during the duration of the trial
- Received an anti-obesity medication within 90 days of screening visit
Note: Other protocol defined Inclusion/ Exclusion Criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Part A
|
Administered per the protocol Administered per the protocol |
|
Placebo Comparator: Part B
|
Administered per the protocol Administered per the protocol |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to 16 weeks
|
Part A |
Up to 16 weeks
|
|
Severity of TEAEs
Time Frame: Up to 16 weeks
|
Part A |
Up to 16 weeks
|
|
Occurrence of TEAEs
Time Frame: Up to 27 weeks
|
Part B |
Up to 27 weeks
|
|
Severity of TEAEs
Time Frame: Up to 27 weeks
|
Part B |
Up to 27 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concentration of REGN20566 in serum
Time Frame: Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Concentration of REGN20566 in serum
Time Frame: Baseline through week 27
|
Part B |
Baseline through week 27
|
|
Occurrence of Anti-Drug Antibodies (ADA) to REGN20566
Time Frame: Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Magnitude of ADA to REGN20566
Time Frame: Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Occurrence of ADA to REGN20566
Time Frame: Baseline through week 27
|
Part B |
Baseline through week 27
|
|
Magnitude of ADA to REGN20566
Time Frame: Baseline through week 27
|
Part B |
Baseline through week 27
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R20566-OB-2626
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD Sharing Time Frame
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD Sharing Access Criteria
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.